Overview of Ambroxol retard

The following table provides a quick reference to the core characteristics of this pharmaceutical preparation.

Property	Description
Active ingredient	Ambroxol hydrochloride
Form	Extended-Release (Retard) Capsule
Pharmacological class	Mucolytic and Secretolytic Agent
Common use	Facilitating the clearance of thick respiratory mucus
Origin	Synthetic (derivative of Bromhexine)

What Type of Medicine is Ambroxol Retard?

Ambroxol retard is classified as a mucolytic agent and secretolytic agent, a synthetic preparation containing the active ingredient Ambroxol hydrochloride. The drug is chemically recognized as a derivative of the substance Bromhexine, establishing its identity within the bronchial therapeutic class. Its primary classification confirms its function is to chemically modify the consistency of thick, tenacious respiratory secretions rather than simply suppressing a cough. Ambroxol is a recognized agent in the management of respiratory conditions, functioning as a mucolytic to help thin and loosen respiratory tract secretions.

Understanding the Extended-Release (Retard) Capsule

The term “retard” designates the preparation as an extended-release capsule, which is a type of modified-release pharmaceutical preparation designed for oral administration. The capsule is specifically engineered to release the active substance, Ambroxol hydrochloride, gradually and consistently over several hours. This design maintains a prolonged concentration of the medication in the body. The rationale for this system is to optimize the therapeutic effect, typically allowing for a less frequent dosing schedule compared to conventional, immediate-release formulations.

General Purpose: Facilitating Airway Clearance

The general purpose of this medication is to facilitate the effective and easier expulsion of sputum by chemically reducing the viscosity (thickness and stickiness) of respiratory secretions. This secretolytic action enhances the body's natural process for transporting and expelling mucus, known as mucociliary clearance. This indicates that the medicine helps support the body’s natural cleaning system to make breathing easier when thick secretions are present, such as in typical scenarios involving acute bronchial congestion.

What side effects are possible with Ambroxol retard?

Possible Side Effects and Safety Information

Official regulatory documents classify possible adverse reactions to Ambroxol based on their frequency and the physiological systems affected. The most frequently observed effects relate to the Gastrointestinal System.

Frequency Classification	Examples of Reactions
Common (up to 1 in 10)	Nausea, Taste disturbance, Numbness of the mouth or throat (Oral/Pharyngeal Hypoaesthesia)
Uncommon (up to 1 in 100)	Vomiting, Diarrhea, Abdominal pain, Dyspepsia, Dry mouth
Rare (up to 1 in 1,000)	Hypersensitivity reactions, Rash, Urticaria

The safety profile also documents several rare but serious adverse reactions. These include potentially life-threatening conditions such as Anaphylactic Reactions (including anaphylactic shock), Angioedema, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome. Official data indicates that SCARs have been reported primarily during the initial phase of treatment.

Regulatory documentation defines certain constraints and precautions. Ambroxol is contraindicated in individuals with a known hypersensitivity to the active substance, Ambroxol hydrochloride, the related substance Bromhexine, or any component of the formulation. Additionally, specific safety caution is advised for use in patients with pre-existing impaired renal function or severe hepatic disease. Official labels also note a safety risk when co-administered with cough suppressants due to the potential for excessive accumulation of secretions.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

Overdose Scope

Feature	Official Regulatory Documentation Summary
Documented Manifestations:	Exaggerated known effects, including short-term restlessness, diarrhea, nausea, and vomiting.
Emergency Action Mandate:	Consult a doctor or seek emergency medical treatment immediately if the recommended dose is exceeded.
Antidote Status:	No specific antidote is known for Ambroxol overdose.

Overdose Classifications

Feature	Official Regulatory Documentation Summary
Severity Context:	Serious symptoms have not been recorded in humans to date. Potential for hypotension is noted only in cases of extreme overdosage.
Management:	Treatment is directed to be mainly symptomatic, and patient observation is required following overdosage.

Official Overdose Statements:

Overdosage is formally documented to present as an exacerbation of common undesirable effects, notably diarrhea, nausea, vomiting, and short-term restlessness.
The regulatory documentation confirms that no specific antidote is known for this overdose.
Procedures such as gastric lavage are not generally indicated and are typically reserved for extremely high overdosage within the first two hours of ingestion.

Connection to the Overall Overdose Profile:

The regulatory profile defines the risk by the manifestation of exaggerated known effects, noting the potential for serious outcomes like hypotension only in situations of extreme overdosage. Regulator-mandated action requires that individuals seek immediate medical attention when an overdose is suspected, with treatment limited to symptomatic and supportive measures due to the confirmed absence of a specific counteracting agent.

Therapeutic Uses of Ambroxol retard

Ambroxol Retard may be part of symptomatic management for respiratory conditions characterized by mucus buildup.

What Ambroxol Retard Treats: Main Uses and Benefits

The use of Ambroxol Retard is consistent with the therapeutic domain of secretolytic therapy, relevant for easing symptoms of abnormal and thick respiratory secretions. The medication is commonly used across conditions characterized by periods of heightened symptoms such as acute bronchitis and chronic bronchitis, where viscid sputum is present.

It is used for managing symptoms that create noticeable physiological strain, addressing issues like difficulty of expectoration and an ineffective productive cough. The extended-release formulation is considered relevant for adult patients managing chronic inflammatory airway diseases such as COPD (Chronic Obstructive Pulmonary Disease), where consistent, long-term support for clearance is needed. This action contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Viscid Secretions

The medicine helps maintain a sense of stability and contributes to improved comfort during periods of heightened symptoms associated with thick secretions.

Regulatory References

European Medicines Agency (EMA) assessment report

Eligibility and Restrictions for Use

Eligibility for Ambroxol Retard

Official regulatory documents define the population eligible for the Ambroxol retard (extended-release) formulation primarily as adults.

Use is absolutely contraindicated in patients with a known hypersensitivity to the active substance, ambroxol hydrochloride, or to the related substance bromhexine. Contraindication also applies to women in the first trimester of pregnancy.

Population Status	Regulatory Classification (Official Labeling)
Pediatric Restriction	The extended-release capsule is not recommended or contraindicated in children under 12 years of age.
Pregnancy/Lactation	Contraindicated in the first trimester; not recommended for breastfeeding women.
Severe Organ Impairment	Use requires caution and often a dose reduction in cases of severe renal or hepatic impairment.
Gastrointestinal History	Caution is advised for patients with a known history of gastric or duodenal ulceration.

These criteria establish mandatory restrictions based on age, physiological status, and metabolic capacity, ensuring the medicine is used only by populations outlined in government-approved prescribing information.

What should I know about interactions with other medicines?

Ambroxol retard is generally considered to have a favorable drug interaction profile, but patients should always inform their healthcare provider about all medicines, supplements, and herbal products they are taking.

Important Drug Interactions

1. Antitussive (Cough Suppressant) Medications

Ambroxol works by thinning and loosening mucus (phlegm) to make it easier to cough up and clear from the airways. Combining it with cough suppressants, which inhibit the cough reflex (e.g., codeine or dextromethorphan), is generally not recommended.
This combination can lead to a potentially dangerous build-up of liquefied mucus in the airways, as the body’s natural mechanism for clearance is blocked.

2. Antibiotics

When Ambroxol is taken concurrently with certain antibiotics, such as amoxicillin, cefuroxime, and erythromycin, it may lead to increased concentrations of the antibiotic in the lung tissue and bronchial secretions.
This interaction is often considered beneficial, as it can potentially enhance the antibiotic's effectiveness in treating respiratory infections. However, a doctor should still be consulted before combining these medications.

3. Other Medicines

No other clinically significant interactions are widely reported, but caution is advised with other mucolytic agents due to the potential for excessive mucus secretion. Individuals with pre-existing liver or kidney conditions may require closer monitoring, as these organs are involved in the metabolism and excretion of Ambroxol. The metabolism of Ambroxol may also be affected by drugs that influence liver enzyme activity.

Mechanism of Action

Ambroxol, a substituted benzylamine, primarily functions as a secretolytic agent by modulating two distinct physiological processes in the respiratory tract. Its action involves the interaction with Type II pneumocytes in the alveolar epithelium and Clara cells in the bronchioles. This interaction specifically stimulates the synthesis and subsequent release of pulmonary surfactant, a lipoprotein that helps to reduce the surface tension of the respiratory fluid layer .

Additionally, the compound alters the structure of mucus by chemically acting on the acidic mucopolysaccharide fibers within the gel matrix. This molecular effect results in the depolymerization of these fibers, which reduces the viscosity and adhesiveness of bronchial secretions. The resulting decrease in sputum viscoelasticity directly facilitates the efficiency of the mucociliary transport system, promoting the clearance of respiratory fluid from the airways.

Dosage and Administration Information

How to Use Ambroxol Retard: Administration Guidelines

This section outlines the instructions for the administration and dosing of Ambroxol Sustained-Release (Retard) capsules or tablets.

Administration Details

Detail	Instruction
Dosage Forms	Sustained-Release Capsule (75 mg) or Sustained-Release OD Tablet (45 mg).
Route	Oral administration.
Standard Dosing	One capsule or one tablet.
Frequency	Once daily (q.d.).
Age Group	The 75 mg capsule/45 mg OD tablet dosage regimen is typically specified for adults.

Procedural and Timing Rules

Administration of the sustained-release capsule or OD tablet must follow specific steps to ensure the medication works as intended.

Capsule Preparation: The sustained-release capsule must be swallowed whole with adequate fluid. It must not be chewed, crushed, or opened as this would destroy the extended-release mechanism.
Timing: The dose is generally recommended to be taken after a meal (or with food).
Missed Dose: If a dose is missed, the instruction is to skip the missed dose and take the next dose at the regular scheduled time. Do not take two doses to make up for a missed dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Ambroxol Retard

Evidence in Chronic Respiratory Conditions

Research has explored the use of this medicine in conditions characterized by fluctuating or episodic manifestations, such as chronic bronchitis and Chronic Obstructive Pulmonary Disease (COPD). The studies conducted have often been randomized clinical trials, comparing the medicine against an inactive substance (placebo) or another intervention. These trials were primarily used in research exploring how symptoms change over time in observed populations, focusing on outcomes reflecting daily functioning or activity level and outcomes related to systemic or functional imbalance.

Long-term studies have monitored patients over defined time intervals, sometimes spanning many months. Findings indicate patterns related to the frequency of periods of heightened symptom activity, often called exacerbations, and patterns related to the frequency of these flare-ups. Evidence suggests that, for certain groups of patients, the medicine may be associated with patterns of change in this frequency. Studies report how symptoms evolved in the observed populations, and research provides context to understanding symptom patterns in these conditions. Findings also indicate changes in patient-reported outcomes describing perceived discomfort.

It is important to understand the scope and research limitation frames of this evidence. For many of these chronic conditions, the follow-up durations were limited in some trials, meaning long-term effects are not fully established beyond the study periods. The results apply only to the populations studied, and for some patient sub-groups, data are still emerging or comparative evidence is lacking against all other available therapies. Certainty remains low for some of these outcomes, and findings describe group patterns, not personal outcomes.

Evidence in Acute Respiratory Conditions

Ambroxol retard was studied for its application in settings evaluating daily-life functioning during temporary illnesses, such as acute bronchitis or other acute respiratory tract infections associated with acute or disruptive episodes where outcomes related to physical discomfort are noticeable. The research conducted included randomized trials and observational settings. These studies focused on assessing short-term or episodic symptom patterns and research examining temporary physiological imbalance.

Findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort, such as cough and difficulty expectorating. Research provides insight into short-term changes that can be measured during the acute phase of illness. Studies help show what has been observed so far, and for many patients in these studies, data show patterns related to patient-reported outcomes describing perceived discomfort.

Research in Children and Special Considerations

The medicine was evaluated in studies involving pediatric populations (children) who also experience conditions involving periods of heightened symptoms related to respiratory illnesses. Findings indicate that the observed patterns were evaluated in pediatric settings. However, when considering special populations, specific subgroup findings are uncertain. The sample sizes were modest in some of the pediatric studies, and evidence is limited for long-term outcomes in very young patients. This highlights that while research has explored the use of the medicine across different age groups, the research provides context but not individual predictions, and further research is ongoing to establish a more complete evidence base for every sub-group within the pediatric population.

Frequently Asked Questions (FAQ)

Common questions about Ambroxol retard (FAQ)

Q: What is the difference between Ambroxol retard and the immediate-release version?

The official product information describes that the retard (extended-release) form is designed to release the active substance gradually into the body over many hours. This sustained action allows for a less frequent dosing schedule, as defined in the official prescribing information. Immediate-release formulations reach their peak concentration faster and typically require administration multiple times per day.

Q: How does the extended-release formula change how the drug works compared to regular tablets?

The extended-release formula modifies the time it takes for the drug to reach its highest level in the blood—a process known as the pharmacokinetic profile. According to official data, the time to maximum concentration (Tmax) is significantly longer for the retard form (approximately 6 hours) compared to immediate-release versions. This formulation is intended to provide a prolonged effect.

Q: Can I stop taking Ambroxol retard suddenly, or does it need to be tapered?

Official drug documentation does not typically include specific instructions regarding the need to stop the medicine gradually (tapered). When used for acute conditions, treatment is generally aligned with symptom resolution. Any decision regarding stopping or altering a treatment regimen should be discussed with a healthcare provider.

Q: What are the main ingredients besides Ambroxol hydrochloride?

The medicine contains the active substance, Ambroxol hydrochloride, along with several non-active ingredients known as excipients. Official documentation lists these non-active components in the 'List of excipients' section, which can vary but often includes substances necessary for the extended-release mechanism, such as various types of polymers or lactose.

Q: What should I be concerned about if I experience a rash while taking Ambroxol retard?

Official documentation notes that a rash is a rare adverse reaction. There have been very few reports of severe skin reactions (SCARs), such as Stevens-Johnson syndrome, in temporal association with ambroxol. If new skin or mucosal lesions appear, official documentation indicates that further advice should be sought and treatment may be discontinued.

Q: How are the side effects of Ambroxol retard officially categorized (common, rare, etc.)?

Side effects in the official product information are classified based on how often they were observed in studies or post-marketing surveillance. This frequency classification includes: Common (may affect up to 1 in 10 people), Uncommon (may affect up to 1 in 100 people), and Rare (may affect up to 1 in 1,000 people). This provides regulatory context on the frequency of reported effects.

Q: Is it true that Ambroxol can have anti-inflammatory properties?

While the primary classification of the medicine is as a mucolytic and secretolytic agent (for thinning mucus), scientific literature reviewed by regulatory bodies reports that ambroxol has also been investigated for other potential properties. These investigated properties include anti-inflammatory and antioxidant effects.

Q: How quickly should I expect to feel the effects of Ambroxol retard?

Based on official pharmacokinetic data, the time it takes for the medicine to reach its maximum concentration in the blood (Tmax) for the extended-release form is approximately six hours after administration. This figure relates to when the drug is most concentrated systemically.

Q: How long does the effect of one dose of Ambroxol retard last?

Official documentation indicates that the terminal elimination half-life of Ambroxol is around 10 hours. The sustained-release formulation is specifically designed to provide a continued effect over a 24-hour period, supporting its established dosing schedule.

Q: Can people with high blood pressure take Ambroxol retard safely?

General warnings in some official product documentation advise caution for use in patients with serious cardiovascular disorders, including hypertension (high blood pressure). This information highlights a need to consider individual health status regarding pre-existing conditions.

Q: Is there a maximum number of days I can continuously take Ambroxol retard?

Official patient information often suggests a limited duration of use for self-medication for acute symptoms. Treatment duration beyond short-term use should be guided by a healthcare professional.

Q: Is it okay to take Ambroxol retard if I am already using an inhaler?

Regulatory warnings typically focus on combinations with cough suppressants and certain antibiotics. Official studies note that the use of Ambroxol with bronchodilators (which may be delivered via inhalers) has been investigated and is not typically described as an unfavorable interaction.

Q: Can Ambroxol retard make me feel dizzy or affect my ability to drive?

Official documentation states there is no specific evidence from post-marketing data suggesting impairment on the ability to drive and use machines. However, if a person experiences side effects like dizziness or fatigue, guidance related to operating machinery should be considered.

Q: Is Ambroxol retard considered a controlled substance?

Ambroxol hydrochloride is not typically classified under the same strict regulations or schedules as a controlled substance (such as certain narcotics or opioids) in most jurisdictions. Its regulatory status usually places it as a non-controlled medicine.

Q: What are the official warnings about using Ambroxol retard during pregnancy or breastfeeding?

Official product information states that Ambroxol hydrochloride crosses the placental barrier. As a precaution, official information describes that its use is generally not advised during the first trimester of pregnancy. Furthermore, the medicine is excreted in breast milk, and its use is generally not advised for mothers who are nursing.

Q: What types of coughs is Ambroxol retard typically used for?

Ambroxol retard is officially indicated for the secretolytic therapy—the thinning and loosening—of acute and chronic bronchopulmonary diseases. These are conditions associated with abnormal mucus secretion and impaired transport, commonly known as a 'chesty' or 'productive' cough.

Q: Is Ambroxol retard available without a prescription in some countries?

The regulatory status of Ambroxol-containing medicines differs across international borders. Official reports indicate that various formulations of the medicine are marketed as both over-the-counter (OTC) medicines and as prescription-only medicines (POM), depending on the national drug authority.

How should Ambroxol retard be stored and disposed of?

Official Storage and Disposal Requirements

This section outlines the mandatory storage and disposal instructions for Ambroxol retard as defined in official regulatory labeling.

Requirement Area	Instructions from Regulatory Labeling
Storage Temperature	Store below 30 C (Controlled Ambient Temperature).
Physical Security	Must be stored out of the reach of children.
Stability	Stability is tied to the expiry date on the sealed packaging.
Disposal of Unused/Expired	Dispose of according to local, regional, or national pharmaceutical waste regulations.
Environmental Precaution	Do not dispose of in wastewater or household trash; avoid release to the environment.

Regulatory documents strictly require that Ambroxol retard is kept below a maximum temperature of 30 C to maintain product quality. As with all medicines, it must be stored in a place inaccessible to children. Final disposal of any unused or expired capsules must follow established pharmaceutical waste protocols to ensure proper handling and environmental protection.

Ambroxol retard